<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205006</url>
  </required_header>
  <id_info>
    <org_study_id>SCFU</org_study_id>
    <nct_id>NCT04205006</nct_id>
  </id_info>
  <brief_title>Stroke Card Long-term Follow-Up</brief_title>
  <official_title>Long-term Outcome of a Pragmatic Trial of Multifaceted Intervention (STROKE-CARD Care) to Reduce Cardiovascular Risk and Improve Quality-of-life After Ischemic Stroke and Transient Ischemic Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VASCage GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krankenhaus Barmherzige Brüder Wien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tirol Kiniken GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We undertook the STROKE-CARD trial (NCT02156778) between 2014 and 2018 with follow-up until
      2019 to evaluate the efficacy of the Post-Stroke disease-management program STROKE-CARD care.
      To further investigate the long-term efficacy of STROKE-CARD care all participants of the
      original trial will be invited for a Long-term in Person follow-up (3 - 6 years).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">December 16, 2019</start_date>
  <completion_date type="Anticipated">March 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The composite CVD outcome: nonfatal stroke (ischemic or hemorrhagic)</measure>
    <time_frame>through study completion, an average of 4,5 years</time_frame>
    <description>Recurrent stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The composite CVD outcome: nonfatal myocardial infarction</measure>
    <time_frame>through study completion, an average of 4,5 years</time_frame>
    <description>Major recurrent (post-discharge) cardiac event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The composite CVD outcome: vascular death</measure>
    <time_frame>through study completion, an average of 4,5 years</time_frame>
    <description>death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, stroke, cardiovascular procedures, and death due to other CV causes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>self-reported health-related quality of life</measure>
    <time_frame>through study completion, an average of 4,5 years</time_frame>
    <description>quantified with the European Quality of Life 5-Dimensions 3-Levels (EQ-5D-3L) overall health utility score14 with rescaled European visual analogue scale weights.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The composite outcome of stroke/TIA</measure>
    <time_frame>through study completion, an average of 4,5 years</time_frame>
    <description>TIA defined as transient neurological deficit &lt;24h and absence of DWI positive lesions on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>through study completion at long term follow up visit, an average of 4,5 years</time_frame>
    <description>death from all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-ED-3L</measure>
    <time_frame>through study completion at long term follow up visit, an average of 4,5 years</time_frame>
    <description>individual 3-level components of the European Quality of Life 5-Dimensions 3-Levels (EQ-5D-3L) questionnaire14 (i.e. mobility, self-care, usual activities, no pain or discomfort, no anxiety or depression) comparing people reporting no problems (level 1) with those reporting problems (level 2 and 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of participants achieving target levels of risk factors in each trial arm of the previous STROKE-CARD trial.</measure>
    <time_frame>through study completion at long term follow up visit, an average of 4,5 years</time_frame>
    <description>Blood pressure &lt;140/&lt;90 mmHg or &lt;130/&lt;85 mmHg in patients with diabetes mellitus, severe renal impairment; HbA1c &lt;7.5% at the study visit in patients with diabetes mellitus; having quit smoking by the study visit in patients that had been smokers at baseline in the STROKE-CARD trial; LDL cholesterol &lt; 100 mg/dL or &lt;70 mg/dL in high-risk patients (i.e. stroke or TIA due to large-artery atherosclerosis or small-vessel occlusion, other evidence of atherosclerotic vascular disease, baseline diabetes; Metabolic Syndrome (NCEP-ATPIII): reduction of component number by 1, physical activity &gt;90 minutes; Platelet inhibitor or oral anticoagulation; Oral anticoagulation (INR 2-3, Time in Therapeutic Range (TTR)&gt;70%) in case of atrial fibrillation (AF), Lipid-lowering medication except for non-atherosclerotic strokes (e.g. vessel dissection).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>TIA</condition>
  <arm_group>
    <arm_group_label>STROKE CARD Cohort</arm_group_label>
    <description>Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and whole blood sample.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients from the STROKE-CARD trial (n=2149) will be contacted by phone or mail for
        possible enrolment in the study. The STROKE-CARD cohort included consecutive patients with
        acute ischaemic stroke or TIA (ABCD2-Score ≥ 3) admitted to one of the two study centres
        (Medical University of Innsbruck, Hospital St. John's of God Vienna) between 2014 and 2018.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion in the previous STROKE-CARD trial (NCT02156778)

          -  Written informed consent

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kiechl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Innsbruck, Austria, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilfried Lang, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital St. John's of God, Vienna, Austria, Department of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Innsbruck, Department of Neurology</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St. John's of God</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Toell T, Boehme C, Mayer L, Krebs S, Lang C, Willeit K, Prantl B, Knoflach M, Rumpold G, Schoenherr G, Griesmacher A, Willeit P, Ferrari J, Lang W, Kiechl S, Willeit J. Pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack -study protocol. BMC Neurol. 2018 Nov 6;18(1):187. doi: 10.1186/s12883-018-1185-2.</citation>
    <PMID>30400876</PMID>
  </results_reference>
  <results_reference>
    <citation>Boehme C, Toell T, Mayer L, Domig L, Pechlaner R, Willeit K, Tschiderer L, Seekircher L, Willeit P, Griesmacher A, Knoflach M, Willeit J, Kiechl S. The dimension of preventable stroke in a large representative patient cohort. Neurology. 2019 Dec 3;93(23):e2121-e2132. doi: 10.1212/WNL.0000000000008573. Epub 2019 Oct 31.</citation>
    <PMID>31672716</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>secondary prevention</keyword>
  <keyword>transient ischemic attack</keyword>
  <keyword>disease management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

